English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Glioblastoma is the most malignant and common primary brain tumor among all central nervous system neoplasm. Despite significant advances in surgical and imaging techniques as well as chemoand radio-therapeutic regimes, the survival of patients suffering with glioblastoma remains gloomy and ranges from 12-14 months. The development of a viable therapeutic strategy for glioblastoma, therefore, requires understanding of the factors that govern the cellular proliferation, robust angiogenesis, extensive infiltration and resistance to apoptosis. Role of chemokine receptor 4 (CXCR4) and its ligand CXCL12 has been described in glioma cell proliferation and motility, therefore this receptor could be a favourable target aimed towards controlling aggression of glioblastoma.

CXCL12/CXCR4 promotes motility and proliferation of glioma cells